Current drug therapy recommendations
for the treatment of attention
deficit hyperactivity disorder
by
Cyr M, Brown CS
Department of Pharmacy Practice and Pharmacoeconomics,
College of Pharmacy, University of Tennessee, Memphis, USA.
Drugs 1998 Aug; 56(2):215-23

ABSTRACT

Attention deficit hyperactivity disorder (ADHD) is characterised by symptoms of inattentiveness and/or hyperactivity-impulsivity which are not appropriate to the child's age. This disorder usually manifests by age 3 and affects up to 5% of school-age children. Although the aetiology is unknown, ADHD appears to have a strong genetic component and to involve dysregulation of the CNS dopaminergic system. Psychostimulants are the mainstay of therapy. The majority of patients will respond to an adequate trial of one of the 3 available stimulants, methylphenidate, dexamphetamine or pemoline. Use of the tricyclic antidepressants as second-line agents is supported by substantial literature. Third-line agents include amfebutamone (bupropion) and clonidine. Other modalities have been studied, but sufficient research is not available to recommend their use over the abovementioned treatments. Assessment of response is best achieved by objective rating scales which allow for input from various environments.

ADHD
Adderall
Pemoline
Selegiline
Bupropion
Tomoxetine
ADHD and sport
Methylphenidate
Methylphenidate SR
Adult Attention-Deficit Disorder
Tomoxetine (Strattera) for ADHD
Antidepressants to treat ADHD in adults
ADHD, amphetamine and the dopamine transporter

Refs
and further reading

HOME
HedWeb
Nootropics
cocaine.wiki
Future Opioids
BLTC Research
MDMA/Ecstasy
Superhapiness?
Utopian Surgery?
The Abolitionist Project
The Hedonistic Imperative
The Reproductive Revolution
Critique of Huxley's Brave New World

The Good Drug Guide
The Responsible Parent's Guide
To Healthy Mood Boosters For All The Family